Table 5.
Post Treatment Factors
| Palbociclib N(%) | Ribociclib N(%) | P | |
|---|---|---|---|
| Total number | 58 | 58 | |
| Need for dose reduction | 7 (12.1) | 9 (15.5) | 0.59 |
| level of dose reduction | 0.75 | ||
| 0 | 51 (87.9) | 49 (84.5) | |
| 1 | 4 (6.9) | 4 (6.9) | |
| 2 | 3 (5.2) | 4 (6.9) | |
| 3 | 0 | 1 (1.7) | |
| Subsequent line | 0.13 | ||
| Chemotherapy | 7 (12) | 8 (13.7) | |
| Everolimus | 14 (24.1) | 20 (34.4) | |
| Number of subsequent lines | 0.52 | ||
| 0 | 38 (65.5) | 32 (55.2) | |
| 1 | 16 (27.6) | 21 (36.2) | |
| 2 | 4 (6.9) | 5 (8.6) | |
| Status at last follow up | 0.7 | ||
| Progression | 25 (43.1) | 27 (46.5) | |
| No progression | 33 (56.9) | 31 (53.4) | |
| Dead | 12 (20.69) | 15 (25.86) | 0.51 |
| Alive | 46 (79.31) | 43 (74.13) | |
| Site of progression | 0.05 | ||
| Bone | 1 (1.72) | 4 (6.9) | |
| Visceral | 15 (25.86) | 20 (34.48) | |
| Bone and visceral | 9 (15.51) | 3 (5.17) |
*statistically significant